Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING

Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer

NCT06148298 · View on ClinicalTrials.gov ↗

Study Summary

The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.

Conditions Studied

Interventions

  • OTHER Non-Human Subject Research study.

Study Locations (1)

Florida

  • University of Central Florida — Orlando

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2023-05-24
Est. Completion 2025-05

Sponsor

University of Central Florida

189 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06148298

The ClinicalTrials.gov registry entry for NCT06148298 describes a study currently listed as recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Central Florida, which has 189 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Cancer of Pancreas appearing as the primary indexed condition, and to 1 intervention — of which Non-Human Subject Research study. is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06148298 reports 1 study location spanning 1 distinct geographic area — top geographies include Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06148298 about?

NCT06148298 is a clinical study titled "Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer". The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.

What is the current status of trial NCT06148298?

This trial is currently recruiting. The enrollment target is 24 participants. The study started on 2023-05-24. Estimated completion is 2025-05.

What conditions does trial NCT06148298 study?

This clinical trial studies the following conditions: Cancer of Pancreas. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06148298?

The interventions under investigation include: Non-Human Subject Research study. (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06148298?

This trial is sponsored by University of Central Florida, which has 189 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06148298 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial